With Additional Active Ingredient Patents (Class 514/223.5)
  • Patent number: 10085998
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: October 2, 2018
    Assignee: Essentialis, Inc.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Patent number: 9585851
    Abstract: Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: March 7, 2017
    Assignee: Palo Alto Investors
    Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
  • Patent number: 9370503
    Abstract: The present invention provides a method for treating an ocular disease in a subject in need thereof, comprising administering an effective amount of a compound of Formula (A) to the subject. Also provided is a pharmaceutical composition for treating an ocular disease, which comprises compound of Formula (A), and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: June 21, 2016
    Inventor: Chi Chou Liao
  • Patent number: 9173848
    Abstract: The present invention is directed to solid stable pharmaceutical fixed dose compositions comprising irbesartan, amlodipine besilate and pharmaceutically acceptable excipients, to their preparation and to their therapeutic application.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: November 3, 2015
    Assignee: SANOFI
    Inventors: Praveen Khullar, Vinay Kolhe, Amol Kulkarni, Shirishbhai Patel, Yashwant Phadke, D Saravanan, Mansing Shingte
  • Patent number: 9169238
    Abstract: The present invention relates to a solid preparation containing a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof, a pH control agent and a diuretic, which is superior in the stability and dissolution property of the compound represented by the formula (I) and the diuretic.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: October 27, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yutaka Tanoue, Junya Nomura
  • Patent number: 9138452
    Abstract: A composition of matter comprises a shelf stable, super critical, CO2 fluid extracted seed oil derived from a cracked biomass of perilla frutescens, the seed oil comprising from about 60 to about 95 percent w/w of PUFAs in a ratio of from about 4:1 to about 6:1 alpha-linolenic acid (ALA) to linoleic acid (LA) and a mixture of selected antioxidants.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: September 22, 2015
    Assignee: U.S. NUTRACEUTICALS, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck, Uy Nguyen
  • Publication number: 20150147394
    Abstract: The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 28, 2015
    Inventors: Je Hak Kim, Kyung Wan Nam, Seo Hun Park, Ju Won Kim, Sang Yeop Kim
  • Patent number: 9029363
    Abstract: The invention relates to a pharmaceutical formulation of the crystalline sodium salt of 4?-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (telmisartan), and to processes for the preparation thereof.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: May 12, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Anja Kohlrausch
  • Publication number: 20150065492
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: June 10, 2014
    Publication date: March 5, 2015
    Inventors: Peter Dragovich, Douglas E. Murphy
  • Publication number: 20140364425
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Inventors: Neil M. Cowen, Richard C. Pasternak
  • Publication number: 20140357626
    Abstract: Inhibitors of HCV replication of formula I, including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R? have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Application
    Filed: December 27, 2012
    Publication date: December 4, 2014
    Inventors: Koen Vandyck, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Publication number: 20140296224
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Nicholas D. ADAMS, Joelle Lorraine Burgess, Michael Gerard Darcy, Carla A. Donatelli, Steven David Knight, Kenneth Allen Newlander, Lance Ridgers, Martha A. Sarpong, Stanley J. Schmidt
  • Publication number: 20140296225
    Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
    Type: Application
    Filed: October 22, 2012
    Publication date: October 2, 2014
    Inventors: Haifeng Tang, Barbara Pio, Nardos Teumelsan, Alexander Pasternak, Reynalda DeJesus
  • Patent number: 8815847
    Abstract: The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a [1,2,4]thiadiazine 1,1-dioxide compound.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: August 26, 2014
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventor: James L. Freddo
  • Publication number: 20140221358
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Application
    Filed: February 5, 2014
    Publication date: August 7, 2014
    Applicant: Amarin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Publication number: 20140206674
    Abstract: The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 24, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Markus ZWICKL
  • Publication number: 20140178471
    Abstract: The present invention in general relates to a pharmaceutical dosage form comprising a multi-layered release formulation formed by co-extrusion. Said formulation in particular comprises a core layer comprising at least one polymer selected from polycaprolactone, ethylcellulose, or combinations thereof; and a coat layer comprising at least one (co)polymer selected from the list comprising: polyethylene oxide; polyethylene glycol; Basic Butylated Methacrylate (co)polymer; a (co)polymer of polyvinylcaprolactam, PEG and polyvinylacetate; or combinations thereof.
    Type: Application
    Filed: August 30, 2012
    Publication date: June 26, 2014
    Applicant: UNIVERSITEIT GENT
    Inventors: Jean Paul Remon, Chris Vervaet
  • Publication number: 20140171424
    Abstract: A method for treating hypertension in a subject in need thereof (e.g., wherein said treatment does not result in an increase in serum uric acid levels, abnormally elevated serum uric acid levels, hyperuricemia, serum uric acid levels of above 6 mg/dL, or in the development of gout in the subject), the method comprising administering to the subject: a. a thiazide diuretic; and b. an organic anion transporter 4 (OAT4) inhibitor. The thiazide diuretic is selected from hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, clorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide. The OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 22, 2012
    Publication date: June 19, 2014
    Applicant: ARDEA BIOSCIENCES, INC.
    Inventor: Jeffrey Miner
  • Publication number: 20140134247
    Abstract: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Adnan Beso, Igor Legen, Sebastjan Reven
  • Patent number: 8697677
    Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 15, 2014
    Assignee: Heart Metabolics Limited
    Inventor: Michael Paul Frenneaux
  • Publication number: 20140073574
    Abstract: A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 13, 2014
    Inventors: Robert L. Roden, Richard J. Gorczynski, Michael J. Gerber
  • Publication number: 20140066396
    Abstract: The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Peter S. Dragovich, Peggy A. Thompson, Frank Ruebsam
  • Patent number: 8652519
    Abstract: A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine besylate by using said composition is also provided.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 18, 2014
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Shuichi Yada, Hideki Yano, Tsuyoshi Nagaike, Misato Yokoi
  • Publication number: 20140031346
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is CR3, and A is and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich
  • Publication number: 20130309301
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: November 7, 2012
    Publication date: November 21, 2013
    Applicant: Essentialis, Inc.
    Inventor: Essentials, Inc.
  • Patent number: 8541393
    Abstract: The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: September 24, 2013
    Assignee: ND Partners, LLC
    Inventor: Frank R. Prosl
  • Publication number: 20130216625
    Abstract: The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance and e.g.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 22, 2013
    Applicant: STEVIA APS
    Inventors: Kjeld Hermansen, Per Bendix Jeppesen
  • Publication number: 20130210778
    Abstract: This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the manufacture of such a formulation for use in the method and to a method of preparing said formulation. The formulation of the present invention is a combination of active principals for use in the prevention of cardiovascular disease, notably ischaemic heart disease (including heart attacks) and stroke among the general adult population.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 15, 2013
    Inventors: Nicholas J. Wald, Malcolm R. Law
  • Publication number: 20130178424
    Abstract: A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
    Type: Application
    Filed: February 13, 2013
    Publication date: July 11, 2013
    Applicant: AbbVie Deutschland GmbH & Co. KG
    Inventor: AbbVie Deutschland GmbH & Co. KG
  • Publication number: 20130172239
    Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Application
    Filed: December 18, 2012
    Publication date: July 4, 2013
    Applicant: AbbVie Inc.
    Inventor: AbbVie Inc.
  • Patent number: 8475839
    Abstract: Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: July 2, 2013
    Assignee: Novartis AG
    Inventors: Yu Cao, Yatindra Joshi, Ping Li, Madhusudhan Pudipeddi, Alan E Royce, Robert F Wagner, Jiahao Zhu
  • Patent number: 8470806
    Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: June 25, 2013
    Assignee: Heart Metabolics Limited
    Inventor: Michael Paul Frenneaux
  • Publication number: 20130116215
    Abstract: The invention features novel pharmaceutical combinations useful for the treatment of neurological diseases, specifically neurodegenerative diseases. The novel pharmaceutical combinations of the invention demonstrate additive or synergistic effect in silico and in vivo. The invention also relates to methods of treatment of neurological and neurodegenerative diseases including the pharmaceutical combinations of the invention.
    Type: Application
    Filed: October 25, 2012
    Publication date: May 9, 2013
    Inventors: Mireia Coma, Patrick Aloy, Albert Pujol, Xavier Gomis, Baldomero Oliva, Alberto Lleó, José Manuel Mas
  • Patent number: 8435563
    Abstract: Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: May 7, 2013
    Assignee: Novartis Pharmaceuticals Corporation
    Inventors: Yu Cao, Yatindra Joshi, Ping Li, Madhusudhan Pudipeddi, Alan E Royce, Robert F Wagner, Jiahao Zhu
  • Publication number: 20130109680
    Abstract: Male Disclosed herein are compositions for ameliorating the lipid producing effects of thiazide therapy. Particularly exemplified herein are compositions containing a thiazide and allopurinol, or some other xanthine oxidase inhibitor.
    Type: Application
    Filed: August 29, 2012
    Publication date: May 2, 2013
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Richard Johnson, Takahiko Nakagawa, Sirirat Reungjui
  • Publication number: 20130078284
    Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 28, 2013
    Inventors: Tzuchi R. Ju, Claudia M. Davila, Yi Gao, Linda E. Gustavson, David LeBlond, Tong Zhu
  • Publication number: 20130039905
    Abstract: The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), clinically isolated syndrome (CIS), tumefactive (tumor-like) M S, Marburg's acute M S, Balós's concentric sclerosis, acute disseminated encephalomyelitis (ADEM), post-vaccinal encephalitis (PVE), post-infectious encephalomyelitis (PIE) and neuromyelitis optica (NMO).
    Type: Application
    Filed: January 4, 2011
    Publication date: February 14, 2013
    Applicant: Neurotec Pharma, S.L.
    Inventors: Marco Pugliese, Josette-Nicole Mahy Gehenne, Manuel Rodríguez Alluè, Juan Francisco Espinosa Parrilla, Noemí Virgili Treserres, Pilar Mancera Aroca, Andrea Pastén Zamorano
  • Publication number: 20130040942
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: July 6, 2012
    Publication date: February 14, 2013
    Inventors: Neil M. Cowen, Iain Dukes
  • Publication number: 20120316156
    Abstract: The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a [1,2,4]thiadiazine 1,1-dioxide compound.
    Type: Application
    Filed: June 6, 2012
    Publication date: December 13, 2012
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventor: James L. Freddo
  • Publication number: 20120302555
    Abstract: The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan compound. With reference to the Recommended Effective Daily Dose of 600 mg, calculated on the basis of eprosartan administered in the form of eprosartan mesylate, it has now been found that a lower dose of eprosartan can be administered when the eprosartan compound is eprosartan acid. This dose is in the range of from 410 to 490 mg, most preferably about 450 mg.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 29, 2012
    Inventors: Paulus A.J. Link, Marcellus M. van der Hulst, Gerhard-Wilhelm Bielenberg, Cornelis R. van den Akker
  • Publication number: 20120283251
    Abstract: The invention is directed to deuterated 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: October 27, 2010
    Publication date: November 8, 2012
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventor: Stephen E. Webber
  • Publication number: 20120238554
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: February 27, 2012
    Publication date: September 20, 2012
    Inventor: Neil M. Cowen
  • Publication number: 20120238555
    Abstract: This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85% of the Irbesartan is dissolved within about 30 minutes using USP apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37° C. with paddle speed of 50 rpm. The formulation can optionally contain at least one additional active ingredient.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 20, 2012
    Applicant: TEVA PHARMACEUTICALS USA, INC.
    Inventors: Gershon Kolatkar, Erela Zisman
  • Publication number: 20120171262
    Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.
    Type: Application
    Filed: March 15, 2012
    Publication date: July 5, 2012
    Inventors: Tzuchi R. Ju, Claudia M. Davila, Yi Gao, Linda E. Gustavson, David LeBlond, Tong Zhu
  • Publication number: 20120164218
    Abstract: Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
    Type: Application
    Filed: January 3, 2012
    Publication date: June 28, 2012
    Inventors: Yu Cao, Yatindra Joshi, Ping Li, Madhusudhan Pudipeddi, Alan Edward Royce, Robert Frank Wagner, Jiahao Zhu
  • Publication number: 20120122773
    Abstract: The present invention provides a compound of formula (I): wherein R1a is optionally substituted C1-6 alkyl, etc.; R1m is hydrogen atom, etc.; G1, G2, G3 and G4 are (i), etc. ((i) G1 is —N(R1b)—, G2 is —CO—, G3 is —C(R1c)(R1d)—, and G4 is oxygen, etc.); R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are each independently optionally substituted C1-6 alkyl, etc.; R2 is optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are each independently a group: -A-B (A is a single bond, etc., B is hydrogen atom, etc.), etc.; n is 1, etc.; R5 is C1-4 alkoxycarbonyl, etc., or a pharmaceutically acceptable salt thereof, which is useful as a renin inhibitor.
    Type: Application
    Filed: June 24, 2010
    Publication date: May 17, 2012
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Satoshi Suetsugu, Nobuhisa Fukuda, Yoshio Nakai, Takashi Takada, Yohei Ikuma, Hiroyuki Nakahira
  • Publication number: 20120115854
    Abstract: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 10, 2012
    Inventors: Suraj Shivappa Shetty, Randy Lee Webb
  • Publication number: 20120114753
    Abstract: The present invention provides a multi-layer tablet comprising: an effervescent layer comprising hydrochlorothiazide or amlodipine or its salt as an active ingredient, a carbonate salt, and an organic acid; and a telmisartan-containing layer.
    Type: Application
    Filed: November 4, 2011
    Publication date: May 10, 2012
    Applicant: DASAN MEDICHEM CO., LTD.
    Inventors: Hyoung-Sun YOO, Man-Ho KWON, Young-Bin BANG, Sung-Woong KIM, Jong-Hyun LEE, Jin-Ho YOO, Bong-Haeng HUR
  • Publication number: 20120107397
    Abstract: The present invention relates to the stable pharmaceutical composition comprising valsartan or a pharmaceutically acceptable salt thereof with mannitol as a filler and povidone as binder. The present invention also relate to the valsartan or pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide or amlodipine or both; and optionally one or more additional excipients.
    Type: Application
    Filed: July 3, 2009
    Publication date: May 3, 2012
    Applicant: Hetero Research Foundation
    Inventors: Bandi Parthasaradhi Reddy, Male Srinivas Reddy, Pothireddy Venkateswar Reddy, Muppidi Vanaja Kumari
  • Publication number: 20120100229
    Abstract: The present invention includes a method of treating or preventing a CNS white matter injury in a patient in need thereof. The invention also includes a method of stimulating proliferation of a CNS cell in a patient in need thereof.
    Type: Application
    Filed: March 25, 2010
    Publication date: April 26, 2012
    Inventor: Scott Rivkees